Format

Send to

Choose Destination
Future Oncol. 2019 Feb;15(6):591-599. doi: 10.2217/fon-2018-0546. Epub 2018 Nov 14.

Apalutamide and its use in the treatment of prostate cancer.

Author information

1
Division of Hematology/Oncology, Department of Medicine, University of California at San Francisco, CA 94158, USA.
2
Helen Diller Family Comprehensive Cancer Center, Department of Medicine, University of California at San Francisco, CA 94158, USA.

Abstract

High-risk nonmetastatic castration-resistant prostate cancer is a lethal disease that previously lacked clear treatment options. Progression to bone metastases is associated with significant morbidity and high cost. Apalutamide, an androgen receptor inhibitor, has substantial clinical response in nonmetastatic castration-resistant prostate cancer. Apalutamide + androgen deprivation therapy is well tolerated and improves metastasis-free survival, progression-free survival and time to symptomatic progression, and is associated with a favorable trend of improved overall survival. Future research is needed to elucidate mechanisms of resistance to treatment with androgen signaling inhibitors.

KEYWORDS:

androgen signaling inhibitor; apalutamide; castration-resistant prostate cancer; nonmetastatic; prostate cancer

PMID:
30426794
PMCID:
PMC6391625
[Available on 2020-02-01]
DOI:
10.2217/fon-2018-0546
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center